These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3584344)

  • 1. Determination of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, a major endogenous ligand substance in uremic serum, by high-performance liquid chromatography with ultraviolet detection.
    Mabuchi H; Nakahashi H
    J Chromatogr; 1987 Mar; 415(1):110-7. PubMed ID: 3584344
    [No Abstract]   [Full Text] [Related]  

  • 2. Underestimation of serum albumin by the bromcresol purple method and a major endogenous ligand in uremia.
    Mabuchi H; Nakahashi H
    Clin Chim Acta; 1987 Jul; 167(1):89-96. PubMed ID: 3665090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of renal transplantation on a major endogenous ligand retained in uremic serum.
    Mabuchi H; Nakahashi H; Hamajima T; Aikawa I; Oka T
    Am J Kidney Dis; 1989 Jan; 13(1):49-54. PubMed ID: 2643310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of hepatic glutathione S-transferases by a major endogenous ligand substance present in uremic serum.
    Mabuchi H; Nakahashi H
    Nephron; 1988; 49(4):281-3. PubMed ID: 3137482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accumulation of furancarboxylic acids in uremic serum as inhibitors of drug binding.
    Niwa T; Takeda N; Maeda K; Shibata M; Tatematsu A
    Clin Chim Acta; 1988 Apr; 173(2):127-38. PubMed ID: 3378354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A major inhibitor of phenytoin binding to serum protein in uremia.
    Mabuchi H; Nakahashi H
    Nephron; 1988; 48(4):310-4. PubMed ID: 3362278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and quantification of a protein-bound ligand in uremic serum.
    Takeda N; Niwa T; Tatematsu A; Suzuki M
    Clin Chem; 1987 May; 33(5):682-5. PubMed ID: 3568353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation and characterization of an endogenous drug-binding inhibitor present in uremic serum.
    Mabuchi H; Nakahashi H
    Nephron; 1986; 44(4):277-81. PubMed ID: 3796769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Displacement by anionic drugs of endogenous ligands bound to albumin in uremic serum.
    Mabuchi H; Nakahashi H
    Ther Drug Monit; 1988; 10(3):261-4. PubMed ID: 3140432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Separation of albumin-binding ligands present in uremic serum by high-performance affinity chromatography.
    Mabuchi H; Nakahashi H
    J Chromatogr; 1990 Aug; 529(2):424-30. PubMed ID: 2229260
    [No Abstract]   [Full Text] [Related]  

  • 11. Highly sensitive simultaneous quantification of indoxyl sulfate and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid in human plasma using ultra-high-performance liquid chromatography coupled with tandem mass spectrometry.
    Oda A; Suzuki Y; Sato B; Sato H; Tanaka R; Ono H; Ando T; Shin T; Mimata H; Itoh H; Ohno K
    J Sep Sci; 2022 May; 45(10):1672-1682. PubMed ID: 35247297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient removal of albumin-bound furancarboxylic acid by protein-leaking hemodialysis.
    Niwa T; Asada H; Tsutsui S; Miyazaki T
    Am J Nephrol; 1995; 15(6):463-7. PubMed ID: 8546166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major albumin-associated fluorescent substance in uremic serum.
    Mabuchi H
    Nephron; 1988; 48(4):328-9. PubMed ID: 3362283
    [No Abstract]   [Full Text] [Related]  

  • 14. Rapid assay for furancarboxylic acid accumulated in uremic serum using high-performance liquid chromatography and on-line mass spectrometry.
    Niwa T; Kawagishi I; Ohya N
    Clin Chim Acta; 1994 Apr; 226(1):89-94. PubMed ID: 8070137
    [No Abstract]   [Full Text] [Related]  

  • 15. Determination of hippuric acid and furanic acid in serum of dialysis patients and control persons by high-performance liquid chromatography.
    Pickert A; Bäuerle A; Liebich HM
    J Chromatogr; 1989 Oct; 495():95-104. PubMed ID: 2613830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of binding site of uremic toxins on human serum albumin.
    Sakai T; Takadate A; Otagiri M
    Biol Pharm Bull; 1995 Dec; 18(12):1755-61. PubMed ID: 8787801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A major endogenous ligand substance involved in renal failure.
    Mabuchi H; Nakahashi H
    Nephron; 1988; 49(4):277-80. PubMed ID: 3412543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel UPLC-MS-MS method for simultaneous determination of seven uremic retention toxins with cardiovascular relevance in chronic kidney disease patients.
    Boelaert J; Lynen F; Glorieux G; Eloot S; Van Landschoot M; Waterloos MA; Sandra P; Vanholder R
    Anal Bioanal Chem; 2013 Feb; 405(6):1937-47. PubMed ID: 23307120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased bilirubin-binding capacity in uremic serum caused by an accumulation of furan dicarboxylic acid.
    Tsutsumi Y; Maruyama T; Takadate A; Shimada H; Otagiri M
    Nephron; 2000 May; 85(1):60-4. PubMed ID: 10773757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremic serum as demonstrated by internal-surface reversed-phase liquid chromatography.
    Niwa T; Takeda N; Tatematsu A; Maeda K
    Clin Chem; 1988 Nov; 34(11):2264-7. PubMed ID: 3141084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.